Background. The outcomes of patients treated with implantable defibrillators were compared between patients with left ventricular ejection fraction .30%o and <309o.
In patients with ventricular tachycardia or ventricular fibrillation, the left ventricular function is an independent predictor of outcome regardless of antiarrhythmic therapy they receive.1-4 In patients with severe ventricular dysfunction, sudden death rates are significant even when they are treated with therapy that is considered effective by electrophysiological studies.'-3 When these patients are treated with implantable defibrillators, sudden death rates are reported to be very low.56 However, nonsudden cardiac death rates remain significant.56 Because nonsudden cardiac deaths include deaths related to arrhythmia such as surgical mortality and "not so sudden" arrhythmic deaths described by Guarnieri et 
Implantation ofAutomatic Defibrillator
The electrode lead system used included a springpatch configuration10 in eight patients, a patch-patch 
Results

Postoperative Course
Three patients died in the hospital within 30 days after surgery, for a surgical mortality of 4.4%. All three patients had an ejection fraction <30%. One patient with coronary disease and an ejection fraction of 29% who had been stable without recurrence of ventricular tachycardia for more than 30 days before surgery developed multiple sustained ventricular tachycardia within 24 hours after the surgery and eventually died because of refractory ventricular tachycardia 22 days after the surgery. One patient with coronary disease and an ejection fraction of 24% who had been stable without heart failure before surgery developed progressive 
Long-term Follow-up
The duration of follow-up was 31±27 months; it was 32±26 months in group 1 and 29±28 months in group 2 (p=NS). Events during the follow-up period are shown in Table 3 . In group 2, four (57%) of seven nonsudden cardiac deaths within 36 months after discharge from the hospital were causally related to the arrhythmia (three surgical deaths and one arrhythmia-related nonsudden death). The actuarial survival rates of all patients free of various events are summarized in Table 4 . Survival rates of all patients free of sudden death and total cardiac death are shown in Figure 1 . Actuarial survival rates of the two groups were separately generated and are shown in Figures 2-5 . Survival rates free of sudden death, sudden death and surgical mortality, total arrhythmia-related death (sudden death, surgical mortality, and arrhythmia-related nonsudden death), and total cardiac death during the initial 36 months of follow-up are compared. The results are also summarized in Table 5 . In Figure 6 , survival rates free of various events of group 2 are separately shown.
Discussion
The results of our study suggest that the outcomes of patients treated with defibrillator therapy are strongly influenced by the degree of ventricular dysfunction. In patients with left ventricular ejection fraction >30%, surgical mortality, sudden death, and total cardiac deaths are rare. In patients with left ventricular ejection fraction <30%, surgical mortality of defibrillator therapy is relatively high. Although sudden death rates are relatively low, total arrhythmia-related deaths including sudden deaths, surgical mortality, and nonsudden arrhythmia-related death are significantly higher than in patients with left ventricular ejection fraction .30%. The majority (57%) of nonsudden deaths within 36 months are causally related to arrhythmia, either caused by the therapy (surgical death) or not prevented by the therapy (nonsudden arrhythmia-related death). Therefore, sudden death rates do not reflect the real benefits and risks of the defibrillator therapy, especially in patients with left ventricular ejection fraction <30%. The total arrhythmia-related death rates instead of sudden death rates should be used to compare the efficacy of defibrillator therapy with that of other therapies in this clinical setting.
Surgical Mortality
The surgical mortality of all patients in our study was similar to many previous studies,11-'4 although others'5 have reported somewhat lower surgical mortality rates. In our study, surgical mortality of patients treated with a defibrillator alone was not significantly different from that of patients treated with a defibrillator and concomitant surgery. This again is similar to other studies.1""14 In a study by Winkle and Thomas,"1 31 of 669 patients (4.6%) without concomitant surgery and nine of 280 patients (3.2%) with concomitant surgery died within 30 days after surgery. Gohn et al,'4 in a study of 271 patients, reported that surgical mortality was 4.0% in all patients, 3.3% in 183 patients without concomitant surgery, and 6.8% in 88 patients with concomitant surgery. The difference between the two groups was not statistically significant. Therefore, surgical mortality of Figure 3) . Total Arrhythmia-Related Death In patients treated with implantable defibrillators, deaths from arrhythmias may be "not so sudden."7 Patients may be resuscitated successfully by the defibrillator initially but may die shortly after the initial event because of refractory ventricular tachycardias.78 Such deaths were defined as nonsudden arrhythmia-related deaths8 in this study. When the total arrhythmia-related death including surgical mortality, sudden death, and nonsudden arrhythmia-related death8 was considered, the outcome of group 2 patients was markedly different from that of group 1 (70% versus 97% at 3 years). Therefore, the benefit of defibrillator therapy in preventing all arrhythmia-related deaths is strongly influenced by the degree of ventricular dysfunction (see Figure 4) . Total Cardiac Death In our study, total cardiac death in all patients was 21.9% at 3 years (see Figures 1 and 5 ). Our results do not appear to be significantly different from those of Winkle et al,15 who reported total cardiac death rates of 18% at 3 years in 270 patients. The results of the Bilitch Report16 (a multicenter registry involving 10 institutions) are also similar to ours. Total cardiac death rates of patients with depressed myocardial function were not reported separately in these studies.15.' 6 Fogoros et a16 reported a survival rate of 67% at 3 years in 40 patients with left ventricular ejection fraction <30%. Luceri et al17 reported that 14 (28%) of 50 patients treated with the defibrillator died at a mean of 9 months after implantation. Mean left ventricular ejection fraction was 23% in patients who died. Tchou et als reported a 2-year survival rate of 86.7% in a study of 25 patients with left ventricular ejection fraction <30% followed up for 18.0±+12.6 months. However, only five patients were followed up for more than 2 years in the study. From these studies617 and our study, it appears that the total cardiac death rate remains substantial in patients with ventricular ejection fraction <30% even when treated with implantable defibrilla- .30%, the survival rate free of total cardiac death appears to be excellent.
Nature of Nonsudden Cardiac Deaths
Sudden death rate, surgical mortality rate, and total cardiac death rate in our study are similar to those of many previous studies when all patients (group 1 and group 2) are compared.1-'6 The results are also similar when patients with left ventricular ejection fraction 230% and <30% are compared separately with other studies.6"1417 Our study is different from previous studies because the nature of nonsudden cardiac deaths in patients with poor ventricular function treated with defibrillators is analyzed more critically. The difference between total cardiac death and sudden cardiac death (Figures 1 and 6 ) has been reported as nonsudden cardiac death in most previous studies. Readers of such studies may get an impression that all nonsudden cardiac deaths are nonarrhythmic deaths caused by progressive heart disease and that deaths from ventricular arrhythmias could be largely eliminated by defibrillator therapy. The fact that the majority of nonsudden cardiac deaths are related to arrhythmia, either caused by the therapy (surgical mortality) or not prevented by the therapy (nonsudden arrhythmia-related deaths), is not apparent from such reportings. The fact that defibrillator therapy merely changes the mode of death of some patients from sudden death to nonsudden death without significant prolongation of life (for example, a prolongation of life for less than 24 hours by our definition) is not apparent from such reportings. Although this method of reporting may not be correct, it does not reflect the true death rate from arrhythmias and overestimates the efficacy of defibrillator therapy in preventing death from arrhythmias. The real death rate from arrhythmia is represented by the total arrhythmia-related death rate. The real nonarrhythmic death rate is represented by the difference between total cardiac death and total arrhythmia-related death ( Figure 6 ). Less 
Study Limitations
The relatively small number of patients in our study may be a limitation. However, the results of our study appear to be not different from many other studies when surgical mortality, sudden death rates, or total cardiac death rates are compared67"1-'7; therefore, our study does not appear to be an aberration. In addition, the relatively small number of patients in our study does not undermine the desirability of the methods used in this study reporting risks and benefits of the therapy and long-term outcomes compared with methods used in other studies. The previous studies5'6 of patients with severe ventricular dysfunction treated with implantable defibrillators were also limited by small numbers of patients (25 and 40 patients, respectively). Further studies will be needed to confirm the results of our study.
Clinical Implications
The results of our study suggest that, as in patients treated medically,1-4 the degree of ventricular dysfunction strongly influences the outcome of patients treated with implantable defibrillators. The 
Conclusions
The indications for defibrillator therapy are expanding and evolving. Further studies are necessary to determine the role of defibrillator therapy and other therapies in various clinical settings. For this purpose, the total arrhythmia-related death rates of patients treated with the defibrillator therapy should be used, because sudden death rates grossly overestimate the benefits of the defibrillator therapy in some clinical settings.
